31. The Compounded Semaglutide Dilemma / Should we trust compounded GLP1 drugs?

In this episode, Thu and Saley dive deep into the drama surrounding GLP-1 receptor agonist medications like Ozempic and Mounjaro. They explore the meteoric rise of these drugs, fueled by celebrity use for weight loss, and the resulting shortages that have led to a clash between pharmaceutical companies, compounding pharmacies, and the FDA.The hosts examine the complex issues at play, including the high costs of these medications, the dangers of improper use and dosing, and the challenges patients face in accessing these potentially life-changing treatments. They also shine a light on the concerning trend of med spas prescribing these drugs for cosmetic purposes, putting patients at risk. With their signature blend of expertise, humor, and passion for healthcare, Thu and Celeste navigate the nuances of this evolving situation, offering insights and advice for both patients and providers. This episode is a must-listen for anyone interested in the intersection of pharmacy, public health, and the ever-changing landscape of modern medicine. Here are 5 key takeaways from the episode: 1. GLP-1 receptor agonists have become a social phenomenon, with celebrities fueling a surge in demand for these medications for weight loss, leading to drug shortages. 2. Compounding pharmacies have stepped in to fill the supply gap, but this has raised safety concerns from pharmaceutical companies about the quality and dosing of compounded versions. 3. The FDA has issued warnings about dosing errors and adverse events associated with compounded GLP-1 medications, highlighting the need for proper medical oversight and patient education. 4. The high cost of these drugs, coupled with limited insurance coverage for weight loss indications, has created an experimental situation, with patients seeking alternatives like sublingual formulations without sufficient evidence. 5. The fragility of the drug supply chain and the competing interests of pharmaceutical companies, compounding pharmacies, and regulatory bodies have created a complex situation that requires transparency, collaboration, and a focus on patient safety. ••••••••••••••••••••••••••••••••••••••••­­­••••••••••• Chapters 00:00 Intro 3:33 GLP1 background 16:29 Drama begins 22:24 Compounding pharmacy claps back 29:52 FDA enters the chat 41:43 Should you trust compounded GLP1? 56:32 Med spas and GLP1... 1:02:40 Drug shortage and its consequences ••••••••••••••••••••••••••••••••••••••••­­­••••••••••• Follow us on social media ▷Hey Rx Friends, We Got This! https://linktr.ee/Heyrxfriends Instagram: https://www.instagram.com/heyrxfriendswgt TikTok: https://www.tiktok.com/@heyrxfriendswgt YouTube: Hey Friends We Got This ▷Thu https://linktr.ee/empoweredpharmd Instagram: https://www.instagram.com/empowered.pharmd/ LinkedIn: https://www.linkedin.com/in/tn-empowered-pharmd Substack: https://drthurx.substack.com/ ▷Saley: Instagram: https://www.instagram.com/reziprep360 LinkedIn: https://www.linkedin.com/in/straore1 TikTok: https://www.linkedin.com/in/straore1 X: ReziPrep360 YouTube: @ReziPrep360 Business inquiries: [email protected] Disclaimer: All opinions are our own.